Results for

Medical Marijuana Research Act of 2019 This bill establishes a new, separate registration process to facilitate medical marijuana research. Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research. Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and offer to sell immature plants and seeds to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.

Medical Cannabis Research Act of 2019 This bill establishes a new, separate registration process for manufacturers of cannabis for research. As a part of this process, the Drug Enforcement Administration must annually assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers. The bill also authorizes health care providers of the Department of Veterans Affairs to provide information to veterans regarding participation in federally approved cannabis clinical trials.

This bill allows a new research tax credit amount for 14% of specified medical research expenditures. It definesspecified medical research expendituresas amounts paid for any qualified research with respect to any qualified countermeasure. Aqualified countermeasureis a drug, biological product, or device that is determined to be a priority (1) to diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; (2) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device; or (3) is a product or technology intended to enhance the use or effect of a drug, biological product, or device. The bill also sets forth a special rule for treatment of specified medical research expenditures paid or incurred in taxable years beginning before January 1, 2021.

This bill allows certain small businesses whose gross receipts do not exceed $1 million a refundable portion of the tax credit for increasing research activities if such businesses are engaging in specified medical research. It definesspecified medical researchas any qualified research with respect to qualified countermeasures. Aqualified countermeasureis a drug, biological product, or device that is determined to be a priority (1) to diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; (2) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device; or (3) is a product or technology intended to enhance the use or effect of a drug, biological product, or device.

National Biomedical Research Act This bill establishes and makes deposits into the Biomedical Innovation Fund for initiatives at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for advancing medical innovation, including by supporting (1) research for disease prevention, diagnosis, and treatment; (2) research for diseases that disproportionally account for federal health care spending; (3) the development, review, and post-market surveillance of medical products; (4) early-career scientists, including researchers from traditionally underrepresented groups; and (5) other innovative research. The bill also requries annual reporting about the fund by the NIH, the FDA, and the Department of the Treasury.

Cannabidiol and Marihuana Research Expansion Act This bill modifies provisions concerning the federal regulation of certain drugs that are deemed to pose a risk of abuse and dependence to facilitate research on, and the use of, medical treatments containing marijuana and its derivatives.

Consensual Donation and Research Integrity Act of 2019 This bill establishes a series of requirements relating to the acquisition or transfer of human bodies or body parts for education, research, or the advancement of medical, dental, or mortuary science, excluding human transplantation. Specifically, the bill establishes registration, record-keeping, labeling, packaging, and disposition requirements.

Collaborative Academic Research Efforts for Tourette Syndrome Act of2019 This bill requires the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome. The NIH must (1) develop a system to collect data on Tourette syndrome, including epidemiological information and data on the availability of medical and social services for individuals with Tourette syndrome and their families; (2) support Collaborative Research Centers for Tourette Syndrome to conduct basic and clinical research; (3) award grants for research on Tourette syndrome symptoms and treatment options for particular patient subpopulations; and (4) designate funding to carry out Tourette syndrome programs and activities.

Medical Innovation Act of 2020 This bill requires certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a relevant settlement agreement regarding specified violations must pay 0.75%-1.5% of its net income to the Department of Health and Human Services for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research. Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year. Priorities for payments must include advancing regulatory science for medical products and research related to diseases that disproportionately account for federal health care spending. A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and subject to prohibitions on introducing or receiving misbranded drugs in interstate commerce.

Medical Innovation Act of 2019 This bill requires certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a relevant settlement agreement regarding specified violations must pay 0.75%-1.5% of its net income to the Department of Health and Human Services for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research. Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year. Priorities for payments must include advancing regulatory science for medical products and research related to diseases that disproportionately account for federal health care spending. A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and subject to prohibitions on introducing or receiving misbranded drugs in interstate commerce.

This resolution commends biomedical researchers and other research entities for their work to improve the health of communities and encourages a continued commitment to biomedical research.

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.) The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients. The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation. The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

Expanding Cannabis Research and Information Act This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription. The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis. Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

Expanding Cannabis Research and Information Act This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription. The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis. Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

VA Medicinal Cannabis Research Act of 2019 This bill requires the Department of Veterans Affairs (VA) to conduct a clinical trial of the effects of medical-grade cannabis on the health outcomes of covered veterans diagnosed with chronic pain, and also those diagnosed with post-traumatic stress disorder. Covered veterans are those who are enrolled in the VA patient enrollment system for hospital care and medical services.

VA Medicinal Cannabis Research Act of 2019 This bill requires the Department of Veterans Affairs (VA) to conduct a clinical trial of the effects of medical-grade cannabis on the health outcomes of covered veterans diagnosed with chronic pain, and also those diagnosed with post-traumatic stress disorder. Covered veterans are those who are enrolled in the VA patient enrollment system for hospital care and medical services.

This resolution expresses support for the designation of a Women's Health Research Day. It also supports efforts to (1) recognize the importance of biomedical and clinical research to women's health, (2) increase awareness of the value of sex- and gender-based biomedical research, and (3) encourage individuals to advocate on behalf of sex- and gender-inclusive research.

U.S. Border Patrol Medical Screening Standards Act The bill directs the Department of Homeland Security (DHS) to (1) research and report to Congress new approaches to improve procedures for providing medical screening of individuals interdicted by U.S. Customs and Border Protection between ports of entry and recommend any necessary corrective actions, and (2) establish an electronic health record system containing the records of individuals in DHS custody that can be accessed by all relevant DHS departments.

This resolution expresses support for the designation of a Women's Health Research Day. It also supports efforts to (1) recognize the importance of biomedical and clinical research to women's health, (2) increase awareness of the value of sex- and gender-based biomedical research, and (3) encourage individuals to advocate on behalf of sex- and gender-inclusive research.

Patient-Centered Outcomes Research Institute Reauthorization Act This bill reauthorizes, and extends funding for, the Patient-Centered Outcomes Research Institute (PCORI) through FY2029. The bill also makes other changes related to the institute, such as (1) requiring health insurance plans to cover routine costs for items and services furnished in connection with certain PCORI-funded clinical trials, and (2) directing the Government Accountability Office to review barriers experienced by PCORI researchers when conducting studies or clinical trials.

Veteran's Prostate Cancer Treatment and Research Act This bill requires the Department of Veterans Affairs (VA) to implement programs and resources related to the diagnosis and treatment of prostate cancer. Specifically, the bill requires the VA to establish in its National Surgery Office a national clinical pathway for all stages of prostate cancer that includes specified elements. A clinical pathway is a health care management tool designed around research and evidence-backed practices that provides direction for the clinical care and treatment of a specific episode of a condition or ailment. The VA must publish the proposed clinical pathway in the Federal Register for public comment. Additionally, the bill requires the VA to publish the established clinical pathway on a public VA website and to update the clinical pathway at least annually. Under the bill, the VA must submit (1) a plan to establish a comprehensive prostate cancer program, and (2) a plan that provides for continual funding for supporting prostate cancer research through the VA Office of Research and Development. The VA must also establish a program evaluation tool to learn best practices of multidisciplinary disease-based implementation. Finally, the VA must establish a real-time, actionable, national prostate cancer registry that is accessible to clinicians and researchers.

Functional Gastrointestinal and Motility Disorders Research Enhancement Act of2019 This bill allows the National Institutes of Health to expand, intensify, and coordinate its activities with respect to functional gastrointestinal and motility disorders (FGIMDs), including by * expanding basic and clinical research into FGIMDs by implementing the research recommendations of the National Commission on Digestive Diseases, * providing support for the establishment of centers of excellence on FGIMDs, * supporting innovative approaches to educating health care providers and patients regarding strategies that improve patient-provider relationships and care, * directing the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to provide the necessary funding for the continued expansion and advancement of the FGIMDs research portfolio, and * directing NIDDK and the Eunice Kennedy Shriver National Institute of Child Health and Human Development to expand research into FGIMDs that impact children. The Department of Health and Human Services may engage in public awareness and education activities to increase understanding and recognition of FGIMDs.

South Asian Heart Health Awareness and Research Act of 2020 This bill establishes a program that supports heart-disease research and awareness among disproportionately affected populations, including the South Asian population, of the United States. Specifically, the Department of Health and Human Services (HHS) must award grants to states for awareness initiatives, educational materials, and research catalogs regarding the prevalence of heart disease, including the association of type 2 diabetes, with respect to the South Asian population. HHS may also support or conduct research in this area.

Humane and Existing Alternatives in Research and Testing Sciences Act of 2019or the HEARTS Act of 2019 This bill directs the National Institutes of Health (NIH) to promote nonanimal research methods. Specifically, NIH must (1) provide incentives for nonanimal research and (2) require the evaluation of viable nonanimal methods before approving animal-based research. Additionally, NIH applications for research grants must include (1) harm-benefit analyses for animal-based research proposals and (2) assurance that nonanimal methods for such research are not available.